Sareum Holdings PLC is a biotechnology company focused on drug discovery and development, primarily targeting cancer and autoimmune diseases. Its key programs include SDC-1801, a selective TYK2/JAK1 inhibitor for autoimmune conditions like psoriasis, and SDC-1802, aimed at cancer applications, particularly in hematological cancers. The company utilizes outsourced resources for its research and development activities and seeks to advance its drug candidates through clinical trials while exploring partnerships for commercialization. Sareum operates primarily in the pharmaceutical sector and is based in the United Kingdom.